TRCT
CCCC icon

Tower Research Capital (TRC)’s C4 Therapeutics CCCC Stock Holding History

Tower Research Capital (TRC)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.6K Sell
8,269
-1,580
-16% -$5.4K ﹤0.01% 2954
2026
Q1 		$25.9K Sell
9,849
-16,131
-62% -$38K ﹤0.01% 3296
2025
Q4 		$49.6K Buy
25,980
+17,566
+209% +$41.6K ﹤0.01% 2418
2025
Q3 		$18.7K Sell
8,414
-32,178
-79% -$77.2K ﹤0.01% 3371
2025
Q2 		$58K Buy
40,592
+33,317
+458% +$48.5K ﹤0.01% 2839
2025
Q1 		$11.6K Sell
7,275
-3,699
-34% -$11K ﹤0.01% 3520
2024
Q4 		$39.5K Sell
10,974
-12,722
-54% -$63.3K ﹤0.01% 2710
2024
Q3 		$135K Buy
23,696
+1,852
+8% +$11.1K ﹤0.01% 1990
2024
Q2 		$101K Buy
21,844
+14,931
+216% +$89K ﹤0.01% 2574
2024
Q1 		$56.5K Sell
6,913
-9,409
-58% -$72.9K ﹤0.01% 2190
2023
Q4 		$92.2K Buy
16,322
+4,063
+33% +$9.26K ﹤0.01% 2711
2023
Q3 		$22.8K Buy
12,259
+2,877
+31% +$8.78K ﹤0.01% 3259
2023
Q2 		$25.8K Buy
9,382
+5,546
+145% +$17.8K ﹤0.01% 3163
2023
Q1 		$12K Buy
3,836
+2,339
+156% +$13.8K ﹤0.01% 4055
2022
Q4 		$9K Sell
1,497
-8,603
-85% -$71.3K ﹤0.01% 4168
2022
Q3 		$89K Buy
10,100
+7,268
+257% +$75.5K ﹤0.01% 2655
2022
Q2 		$21K Sell
2,832
-8,204
-74% -$72.2K ﹤0.01% 3729
2022
Q1 		$268K Buy
11,036
+6,209
+129% +$151K ﹤0.01% 1529
2021
Q4 		$155K Buy
4,827
+2,003
+71% +$79.2K ﹤0.01% 1950
2021
Q3 		$126K Buy
2,824
+1,680
+147% +$71.9K ﹤0.01% 2202
2021
Q2 		$44K Sell
1,144
-932
-45% -$33.4K ﹤0.01% 3122
2021
Q1 		$76K Buy
2,076
+1,790
+626% +$71.2K ﹤0.01% 2793
2020
Q4 		$9K Buy
+286
New +$8.29K ﹤0.01% 4372

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tower Research Capital (TRC)'s CCCC Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its C4 Therapeutics (CCCC) stake by 16% in Q2 2026, selling an estimated $5.4K and leaving 8,269 shares worth $38.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2954.

Tower Research Capital (TRC) first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $268K in Q1 2022. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Tower Research Capital (TRC) held 8,269 shares of C4 Therapeutics worth $38.6K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,580 C4 Therapeutics shares in Q2 2026, an estimated $5.4K.
  • C4 Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2954 holding.
  • Tower Research Capital (TRC) first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s C4 Therapeutics position peaked at $268K in Q1 2022.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.